التفاصيل البيبلوغرافية
| العنوان: |
Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. |
| المؤلفون: |
Brown, Sue A., Beck, Roy W., Raghinaru, Dan, Buckingham, Bruce A., Laffel, Lori M., Wadwa, R. Paul, Kudva, Yogish C., Levy, Carol J., Pinsker, Jordan E., Dassau, Eyal, Doyle III, Francis J., Ambler-Osborn, Louise, Anderson, Stacey M., Church, Mei Mei, Ekhlaspour, Laya, Forlenza, Gregory P., Levister, Camilla, Simha, Vinaya, Breton, Marc D., Kollman, Craig |
| المصدر: |
Diabetes Care; Aug2020, Vol. 43 Issue 8, p1822-1828, 7p |
| مصطلحات موضوعية: |
BLOOD sugar analysis, RESEARCH, CLINICAL trials, BLOOD sugar monitoring, RESEARCH methodology, TYPE 1 diabetes, BLOOD sugar, PROGNOSIS, EVALUATION research, MEDICAL cooperation, INSULIN, TREATMENT effectiveness, COMPARATIVE studies, RANDOMIZED controlled trials, INSULIN pumps, HYPOGLYCEMIA, RESEARCH funding, SUBCUTANEOUS injections |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Objective: Limited information is available about glycemic outcomes with a closed-loop control (CLC) system compared with a predictive low-glucose suspend (PLGS) system.Research Design and Methods: After 6 months of use of a CLC system in a randomized trial, 109 participants with type 1 diabetes (age range, 14-72 years; mean HbA1c, 7.1% [54 mmol/mol]) were randomly assigned to CLC (N = 54, Control-IQ) or PLGS (N = 55, Basal-IQ) groups for 3 months. The primary outcome was continuous glucose monitor (CGM)-measured time in range (TIR) for 70-180 mg/dL. Baseline CGM metrics were computed from the last 3 months of the preceding study.Results: All 109 participants completed the study. Mean ± SD TIR was 71.1 ± 11.2% at baseline and 67.6 ± 12.6% using intention-to-treat analysis (69.1 ± 12.2% using per-protocol analysis excluding periods of study-wide suspension of device use) over 13 weeks on CLC vs. 70.0 ± 13.6% and 60.4 ± 17.1% on PLGS (difference = 5.9%; 95% CI 3.6%, 8.3%; P < 0.001). Time >180 mg/dL was lower in the CLC group than PLGS group (difference = -6.0%; 95% CI -8.4%, -3.7%; P < 0.001) while time <54 mg/dL was similar (0.04%; 95% CI -0.05%, 0.13%; P = 0.41). HbA1c after 13 weeks was lower on CLC than PLGS (7.2% [55 mmol/mol] vs. 7.5% [56 mmol/mol], difference -0.34% [-3.7 mmol/mol]; 95% CI -0.57% [-6.2 mmol/mol], -0.11% [1.2 mmol/mol]; P = 0.0035).Conclusions: Following 6 months of CLC, switching to PLGS reduced TIR and increased HbA1c toward their pre-CLC values, while hypoglycemia remained similarly reduced with both CLC and PLGS. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Care is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder